# Annovis Bio, Inc. (ANVS)

- Sector: Healthcare · Industry: Biotechnology
- SEC CIK: 0001477845 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001477845))
- Full page: https://inspectstocks.com/stocks/anvs
- Data as of: price 2026-09-25; newest filing used 2026-08-14; latest fiscal period ended 2026-06-30

## Grade

**F** on the balance-sheet rubric used for lenders, 0 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed | -$49.5M |  |
| Earnings growing overall | failed | -$49.5M | -$33.4M |
| Earnings growing recently | failed | -$49.5M | -$28.9M |
| Earns well on its assets | failed | -224.7% |  |
| Book value per share growing | failed | $0.82 | $3.47 |

Business quality (the + / − mark): 1 of 2 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Good return on equity | failed | -293.9% |  |
| Debt under control | passed | 0.03 |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $0.00 |
| Net income, trailing twelve months | -$49.5M |
| Return on equity | -293.9% |
| Debt to equity | 0.03 |
| Diluted EPS, trailing twelve months | -$1.79 |
| Share price | $1.31 |
| Market value | $55.8M |

## More on this company

- [Overview](https://inspectstocks.com/stocks/anvs)
- [Financial statements](https://inspectstocks.com/stocks/anvs/financials)
- [Competitors](https://inspectstocks.com/stocks/anvs/peers)
- [Earnings](https://inspectstocks.com/stocks/anvs/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.